Evidence map›Paper›PMID 29636521›Full record

ArticleScientific reports2018

Exploration of the effect of sequence variations located inside the binding pocket of HIV-1 and HIV-2 proteases.

Dhoha Triki, Telli Billot, Benoit Visseaux, Diane Descamps, Delphine Flatters, Anne-Claude Camproux, Leslie Regad

Open access · goldAbstract readComparative Study
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Dhoha TrikiMolécules thérapeutiques in silico (MTi), INSERM UMR-, S973, Paris, France.
Telli BillotMolécules thérapeutiques in silico (MTi), INSERM UMR-, S973, Paris, France.
Benoit VisseauxIAME, UMR 1137, INSERM, Laboratoire de Virologie, Hôpital Bichât, AP-HP, Paris, France.ORCID 0000-0002-9279-5538
Diane DescampsIAME, UMR 1137, INSERM, Laboratoire de Virologie, Hôpital Bichât, AP-HP, Paris, France.
Delphine FlattersMolécules thérapeutiques in silico (MTi), INSERM UMR-, S973, Paris, France.
Anne-Claude CamprouxMolécules thérapeutiques in silico (MTi), INSERM UMR-, S973, Paris, France.
Leslie RegadMolécules thérapeutiques in silico (MTi), INSERM UMR-, S973, Paris, France. leslie.regad@univ-paris-diderot.fr.
Inserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HIV-2 protease (PR2) is naturally resistant to most FDA (Food and Drug Administration)-approved HIV-1 protease inhibitors (PIs), a major antiretroviral class. In this study, we compared the PR1 and PR2 binding pockets extracted from structures complexed with 12 ligands. The comparison of PR1 and PR2 pocket properties showed that bound PR2 pockets were more hydrophobic with more oxygen atoms and fewer nitrogen atoms than PR1 pockets. The structural comparison of PR1 and PR2 pockets highlighted structural changes induced by their sequence variations and that were consistent with these property changes. Specifically, substitutions at residues 31, 46, and 82 induced structural changes in their main-chain atoms that could affect PI binding in PR2. In addition, the modelling of PR1 mutant structures containing V32I and L76M substitutions revealed a cooperative mechanism leading to structural deformation of flap-residue 45 that could modify PR2 flexibility. Our results suggest that substitutions in the PR1 and PR2 pockets can modify PI binding and flap flexibility, which could underlie PR2 resistance against PIs. These results provide new insights concerning the structural changes induced by PR1 and PR2 pocket variation changes, improving the understanding of the atomic mechanism of PR2 resistance to PIs.

Indexed as

Models, MolecularAmino Acid SequenceDrug DiscoveryHIVHIV-1HIV-2HIV ProteaseHIV Protease InhibitorsProtein BindingProtein ConformationSequence Analysis, ProteinHIV ProteaseHIV Protease Inhibitorsp16 protease, Human immunodeficiency virus 1p16 protease, Human immunodeficiency virus 2

Identifiers

PMID29636521
PMCPMC5893546
OpenAlexW2805447705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.